Tango Therapeutics Inc
TNGX8.700USD
+0.170+1.99%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
970.63MMarket Cap
LossP/E TTM
More Details of Tango Therapeutics Inc Company
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Tango Therapeutics Inc Info
Ticker SymbolTNGX
Company nameTango Therapeutics Inc
IPO dateSep 03, 2020
CEOWeber (Barbara)
Number of employees155
Security typeOrdinary Share
Fiscal year-endSep 03
Address201 Brookline Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02215
Phone18573204900
Websitehttps://www.tangotx.com/
Ticker SymbolTNGX
IPO dateSep 03, 2020
CEOWeber (Barbara)
Company Executives of Tango Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
Mr. Kanishka Pothula
Mr. Kanishka Pothula
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
7.99%
EcoR1 Capital, LLC
7.90%
Boxer Capital Management, LLC
7.26%
TCG Crossover Management, LLC
6.34%
Third Rock Ventures, LLC
5.85%
Other
64.66%
Shareholders
Shareholders
Proportion
Farallon Capital Management, L.L.C.
7.99%
EcoR1 Capital, LLC
7.90%
Boxer Capital Management, LLC
7.26%
TCG Crossover Management, LLC
6.34%
Third Rock Ventures, LLC
5.85%
Other
64.66%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.41%
Investment Advisor
32.59%
Investment Advisor/Hedge Fund
19.77%
Venture Capital
8.62%
Corporation
3.69%
Research Firm
1.45%
Individual Investor
1.26%
Family Office
0.53%
Bank and Trust
0.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
309
124.59M
94.78%
+2.75M
2025Q2
313
119.32M
107.84%
-16.77M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Farallon Capital Management, L.L.C.
9.16M
8.23%
+4.55M
+98.59%
Jun 30, 2025
EcoR1 Capital, LLC
10.63M
9.55%
--
--
Jun 30, 2025
Boxer Capital Management, LLC
9.77M
8.78%
-609.51K
-5.87%
Jun 30, 2025
TCG Crossover Management, LLC
10.74M
9.65%
--
--
Jun 30, 2025
Third Rock Ventures, LLC
14.06M
12.64%
-1.59M
-10.18%
Sep 25, 2025
Woodline Partners LP
6.03M
5.42%
+5.52M
+1091.24%
Jun 30, 2025
Invus Public Equities Advisors, LLC
5.88M
5.29%
+2.52M
+74.84%
Sep 19, 2025
Nextech Invest, Ltd.
5.53M
4.97%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
4.44%
+1.21M
+32.30%
Jun 30, 2025
The Vanguard Group, Inc.
4.03M
3.62%
+151.25K
+3.90%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.09%
Invesco Dorsey Wright Healthcare Momentum ETF
0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
0.91%
State Street SPDR S&P Biotech ETF
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.15%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.09%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.91%
State Street SPDR S&P Biotech ETF
Proportion0.43%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Vanguard US Momentum Factor ETF
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tango Therapeutics Inc?
The top five shareholders of Tango Therapeutics Inc are:
Farallon Capital Management, L.L.C. holds 9.16M shares, accounting for 8.23% of the total shares.
EcoR1 Capital, LLC holds 10.63M shares, accounting for 9.55% of the total shares.
Boxer Capital Management, LLC holds 9.77M shares, accounting for 8.78% of the total shares.
TCG Crossover Management, LLC holds 10.74M shares, accounting for 9.65% of the total shares.
Third Rock Ventures, LLC holds 14.06M shares, accounting for 12.64% of the total shares.
Farallon Capital Management, L.L.C. holds 9.16M shares, accounting for 8.23% of the total shares.
EcoR1 Capital, LLC holds 10.63M shares, accounting for 9.55% of the total shares.
Boxer Capital Management, LLC holds 9.77M shares, accounting for 8.78% of the total shares.
TCG Crossover Management, LLC holds 10.74M shares, accounting for 9.65% of the total shares.
Third Rock Ventures, LLC holds 14.06M shares, accounting for 12.64% of the total shares.
What are the top three shareholder types of Tango Therapeutics Inc?
The top three shareholder types of Tango Therapeutics Inc are:
Farallon Capital Management, L.L.C.
EcoR1 Capital, LLC
Boxer Capital Management, LLC
Farallon Capital Management, L.L.C.
EcoR1 Capital, LLC
Boxer Capital Management, LLC
How many institutions hold shares of Tango Therapeutics Inc (TNGX)?
As of 2025Q3, 309 institutions hold shares of Tango Therapeutics Inc, with a combined market value of approximately 124.59M, accounting for 94.78% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.06%.
What is the biggest source of revenue for Tango Therapeutics Inc?
In --, the -- business generated the highest revenue for Tango Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
